SYNERGY-NASH

The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.

Definition

Phase 2 randomized trial of tirzepatide in adults with biopsy-confirmed MASH (formerly NASH) + significant fibrosis. Loomba 2024 NEJM (PMID 38856224). Primary endpoint: MASH resolution without worsening fibrosis at week 52 — a histologic endpoint requiring liver biopsy. 62% of patients on 15 mg achieved resolution vs 10% placebo. Positions GLP-1s as first-in-class systemic therapy for MASH outside FXR agonists.

SYNERGY-NASH trial deep-dive →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Major trials

STEP-1
SURMOUNT-1
SELECT
FLOW
SURMOUNT-OSA
STEP-TEENS
MACE (Major Adverse Cardiovascular Events)
KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire — Clinical Summary Score)
ATTAIN-1
IWQOL-Lite-CT
STEP-4 (withdrawal trial)
LEADER (trial)
FLOW (trial)

Looking for more depth?

SYNERGY-NASH trial deep-dive
Browse the full GLP-1 glossary (124 terms across 8 categories)
Research articles — primary-source deep dives
Tools and calculators
Compare GLP-1 telehealth providers